364 related articles for article (PubMed ID: 33978986)
1. Real-world treatment escalation from metformin monotherapy in youth-onset Type 2 diabetes mellitus: A retrospective cohort study.
Vajravelu ME; Hitt TA; Amaral S; Levitt Katz LE; Lee JM; Kelly A
Pediatr Diabetes; 2021 Sep; 22(6):861-871. PubMed ID: 33978986
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns in Patients With Newly Diagnosed Type 2 Diabetes in China: A Retrospective, Longitudinal Database Study.
Wang C; Gao Y; Zhu L; Huang M; Wu Y; Xuan J
Clin Ther; 2019 Aug; 41(8):1440-1452. PubMed ID: 31155146
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
Yurgin N; Secnik K; Lage MJ
Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
[TBL] [Abstract][Full Text] [Related]
5. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment initiation for type 2 diabetes in Australia: are the guidelines being followed?
Wood SJ; Magliano DJ; Bell JS; Shaw JE; Keen CS; Ilomäki J
Diabet Med; 2020 Aug; 37(8):1367-1373. PubMed ID: 31557346
[TBL] [Abstract][Full Text] [Related]
7. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs.
Campbell DJT; Campbell DB; Ogundeji Y; Au F; Beall R; Ronksley PE; Quinn AE; Manns BJ; Hemmelgarn BR; Tonelli M; Spackman E
Diabet Med; 2021 Sep; 38(9):e14622. PubMed ID: 34133781
[TBL] [Abstract][Full Text] [Related]
8. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
[TBL] [Abstract][Full Text] [Related]
9. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.
Raebel MA; Ellis JL; Schroeder EB; Xu S; O'Connor PJ; Segal JB; Butler MG; Schmittdiel JA; Kirchner HL; Goodrich GK; Lawrence JM; Nichols GA; Newton KM; Pathak RD; Steiner JF
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):699-710. PubMed ID: 24639086
[TBL] [Abstract][Full Text] [Related]
10. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.
Eurich DT; Simpson SH; Majumdar SR; Johnson JA
Pharmacotherapy; 2005 Jun; 25(6):810-6. PubMed ID: 15927899
[TBL] [Abstract][Full Text] [Related]
11. Treatment of type 2 diabetes mellitus in children and adolescents.
Zuhri-Yafi MI; Brosnan PG; Hardin DS
J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():541-6. PubMed ID: 12017229
[TBL] [Abstract][Full Text] [Related]
12. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
[TBL] [Abstract][Full Text] [Related]
13. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019.
Sun JW; Hernández-Díaz S; Bourgeois FT; Haneuse S; Brill G; Bateman BT; Huybrechts KF
Diabetes Obes Metab; 2021 Feb; 23(2):444-454. PubMed ID: 33118291
[TBL] [Abstract][Full Text] [Related]
15. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
[TBL] [Abstract][Full Text] [Related]
16. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
Fu AZ; Sheehan JJ
Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
[TBL] [Abstract][Full Text] [Related]
17. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
18. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy.
Hazel-Fernandez L; Xu Y; Moretz C; Meah Y; Baltz J; Lian J; Kimball E; Bouchard J
Curr Med Res Opin; 2015; 31(9):1703-16. PubMed ID: 26154837
[TBL] [Abstract][Full Text] [Related]
19. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
Ghotbi AA; Køber L; Finer N; James WP; Sharma AM; Caterson I; Coutinho W; Van Gaal LF; Torp-Pedersen C; Andersson C
Diabetes Care; 2013 Nov; 36(11):3746-53. PubMed ID: 24089540
[TBL] [Abstract][Full Text] [Related]
20. Retrospective chart review of children with type 2 diabetes mellitus evaluating the efficacy of metformin vs. insulin vs. combination insulin/metformin.
Meyer SL; Hoffman RP
South Med J; 2011 Oct; 104(10):684-8. PubMed ID: 21941156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
